fenoterol vs fluticasone furoate/vilanterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
fenoterol
Marketed by Boehringer Ingelheim
NCT02177370 · Phase 3 · terminated
This was a randomized, double-blind, active-controlled crossover study, but it enrolled only 19 participants and one of its two primary measures is a laboratory receptor-density biomarker rather than a direct asthma outcome, and no results have been posted.
No aligned efficacy figure on record for this race.
fluticasone furoate/vilanterol · Breo Ellipta
Marketed by GlaxoSmithKline
NCT01086384 · Phase 3 · completed
This was a randomized, triple-blind, active-controlled trial with approximately 2,019 treated participants. Its primary hard clinical endpoint—having one or more severe asthma exacerbations—favored fluticasone furoate/vilanterol and was statistically significant.
Reported efficacy
Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): FF/VI 100/25 µg 154/1009 vs FF 100 µg 186/1010 (met)
Result source: NCT01086384
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | fenoterol | fluticasone furoate/vilanterol |
|---|---|---|
| Severe exacerbations, annualised rate | —Not reported | —Trial running · NCT05757102 |
| Trough FEV1, change | —Not reported | 0.4 vs 0.2+0.2 vs placeboNCT011651388 other results
|
| ACQ-5, change | —Not reported | -1.2 vs -1.1vs FFNCT032481281 other result
|
| OCS dose reduction | —Not reported | —Trial running · NCT05757102 |
Severe exacerbations, annualised rate
- fenoterol
- —Not reported
- fluticasone furoate/vilanterol
- —Trial running · NCT05757102
Trough FEV1, change
- fenoterol
- —Not reported
- fluticasone furoate/vilanterol
- 0.4 vs 0.2+0.2 vs placeboNCT01165138
8 other results
- 0.4 vs 0.2 NCT01134042
- 0.5 vs 0.4 NCT01686633
- 0.3 vs 0.3 NCT01086384
- 0.3 vs 0.3 NCT01147848
- 0.4 vs 0.4 NCT01686633
- 0.3 vs 0.3 NCT03248128
- -0.1 vs -0.1 NCT02094937
- 0.3 vs 0.2 NCT03248128
ACQ-5, change
- fenoterol
- —Not reported
- fluticasone furoate/vilanterol
- -1.2 vs -1.1vs FFNCT03248128
1 other result
- -1.3 vs -1.1 NCT03248128
OCS dose reduction
- fenoterol
- —Not reported
- fluticasone furoate/vilanterol
- —Trial running · NCT05757102
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
fenoterol: no structured comparison results are available for Asthma.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. fenoterol: 0 of 4 rows · fluticasone furoate/vilanterol: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | fluticasone furoate/vilanterol |
|---|---|
| Dropout rate | —100/25 µga NCT01086384 · Phase 3 show 16 more results—200/25 µg OD NCT01018186 · Phase 3 —100/25 µg OD NCT01018186 · Phase 3 — NCT03248128 · Phase 3 · Asthma · phase 3 10.9%100/25 µg OD NCT01165138 · Phase 3 7.2%200/25 µg OD NCT01686633 · Phase 3 9.2%100/25 µg OD NCT01686633 · Phase 3 14.2%200/25 µg OD NCT01134042 · Phase 3 · combination · Asthma · phase 3 —100/25 µg OD NCT01147848 · Phase 3 · Asthma · phase 3 —100/25 µg QD NCT02730351 · Phase 4 · registry result, not featured evidence 6.2%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination 14.4%100/25 µg Once Daily NCT01498679 · Phase 3 · registry result, not featured evidence 12.3%200/25 µg Once Daily NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 —100 µg/25 µg NCT01453023 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —100/25 µga NCT01086384 · Phase 3 show 16 more results—200/25 µg OD NCT01018186 · Phase 3 —100/25 µg OD NCT01018186 · Phase 3 — NCT03248128 · Phase 3 · Asthma · phase 3 1%100/25 µg OD NCT01165138 · Phase 3 0.9%200/25 µg OD NCT01686633 · Phase 3 0.9%100/25 µg OD NCT01686633 · Phase 3 3.6%200/25 µg OD NCT01134042 · Phase 3 · combination · Asthma · phase 3 —100/25 µg OD NCT01147848 · Phase 3 · Asthma · phase 3 —100/25 µg QD NCT02730351 · Phase 4 · registry result, not featured evidence 1.6%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination 2.6%100/25 µg Once Daily NCT01498679 · Phase 3 · registry result, not featured evidence 1.3%200/25 µg Once Daily NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 —100 µg/25 µg NCT01453023 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 4.1%100/25 µga NCT01086384 · Phase 3 show 16 more results0.5%200/25 µg OD NCT01018186 · Phase 3 1.5%100/25 µg OD NCT01018186 · Phase 3 1.1% NCT03248128 · Phase 3 · Asthma · phase 3 0%100/25 µg OD NCT01165138 · Phase 3 0.3%200/25 µg OD NCT01686633 · Phase 3 1.2%100/25 µg OD NCT01686633 · Phase 3 3%200/25 µg OD NCT01134042 · Phase 3 · combination · Asthma · phase 3 1%100/25 µg OD NCT01147848 · Phase 3 · Asthma · phase 3 1.4%100/25 µg QD NCT02730351 · Phase 4 · registry result, not featured evidence 1.2%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence 0.8%100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence 0%100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination 1.3%100/25 µg Once Daily NCT01498679 · Phase 3 · registry result, not featured evidence 0.6%200/25 µg Once Daily NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 0%100 µg/25 µg NCT01453023 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 100/25 µga headache 18.6% nasopharyngitis 15.4% upper respiratory tract infection 7.2% NCT01086384 · Phase 3 show 15 more results200/25 µg OD headache 17.3% upper respiratory tract infection 14.9% nasopharyngitis 9.4% NCT01018186 · Phase 3 100/25 µg OD headache 19.4% upper respiratory tract infection 16.9% nasopharyngitis 12.4% NCT01018186 · Phase 3 nasopharyngitis 10.4% upper respiratory tract infection 7% rhinitis allergic 4.2% NCT03248128 · Phase 3 · Asthma · phase 3 200/25 µg OD headache 8.4% nasopharyngitis 7.2% upper respiratory tract infection 2% NCT01686633 · Phase 3 100/25 µg OD headache 8.4% nasopharyngitis 6.4% upper respiratory tract infection 2.3% NCT01686633 · Phase 3 200/25 µg OD nasopharyngitis 12.7% headache 5.6% bronchitis 3.6% NCT01134042 · Phase 3 · combination · Asthma · phase 3 100/25 µg OD nasopharyngitis 11.4% headache 8.4% upper respiratory tract infection 6.2% NCT01147848 · Phase 3 · Asthma · phase 3 100/25 µg QD upper respiratory tract infection 6.8% NCT02730351 · Phase 4 · registry result, not featured evidence 100/25 mcg Once Daily nasopharyngitis 12.1% headache 8.1% bronchitis 4% NCT02301975 · Phase 3 · registry result, not featured evidence 100 mcg once daily nasopharyngitis 17.9% NCT02094937 · Phase 3 · registry result, not featured evidence 100/25 mcg once daily nasopharyngitis 15.6% NCT02094937 · Phase 3 · registry result, not featured evidence · combination 100/25 µg Once Daily upper respiratory tract infection 7.2% (placebo 9.1%) headache 4.6% (placebo 1.9%) nasopharyngitis 4.6% (placebo 8.4%) NCT01498679 · Phase 3 · registry result, not featured evidence 200/25 µg Once Daily upper respiratory tract infection 8.4% nasopharyngitis 3.9% rhinitis allergic 3.2% NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 100 µg/25 µg bronchitis 4% conjunctivitis 4% headache 4% NCT01453023 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 13 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
fluticasone furoate/vilanterol
show 8 more results
show 1 more result
show 6 more results
show 1 more result
show 1 more result
show 1 more result
show 3 more results
show 4 more results
show 3 more results
show 4 more results
+ 19 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fenoterol's landscape · fluticasone furoate/vilanterol's landscape